NeuroSense Therapeucs Ltd. announced that it has opened an EU Office as well as been granted the Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval. The EMA already granted PrimeC Orphan Drug Status for the treatment of ALS.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.23 USD | -2.38% | -13.38% | +56.69% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.69% | 21.32M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- NRSN Stock
- News NeuroSense Therapeutics Ltd.
- European Medicines Agency Grants the Small and Medium-Sized Enterprise Status of Neurosense Therapeutics Ltd